Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00838799 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety and Efficacy of RGH-896 in Patients With Diabetic Peripheral Neuropathic Pain
A Phase 2 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 458
- Enrollment target
NCT00838799 is a Phase 2 study that has completed, run by Forest Laboratories. The registered enrollment target is 458 participants.
The verdict
NCT00838799, a Phase 2 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 458 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and efficacy of RGH-896 in patients with diabetic peripheral neuropathic pain.
Interventions
- DRUG placebo
- DRUG pregabalin
- DRUG RGH-896
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 458 participants |
| Start Date | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00838799
The ClinicalTrials.gov registry entry for NCT00838799 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 458 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00838799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00838799 about?
NCT00838799 is a clinical study titled "Study of the Safety and Efficacy of RGH-896 in Patients With Diabetic Peripheral Neuropathic Pain". This study is designed to evaluate the safety and efficacy of RGH-896 in patients with diabetic peripheral neuropathic pain.
What is the current status of trial NCT00838799?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 458 participants. The study started on 2009-02.
What interventions are being tested in trial NCT00838799?
The interventions under investigation include: placebo (DRUG), pregabalin (DRUG), RGH-896 (DRUG).
Who is sponsoring clinical trial NCT00838799?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.